Role of the microvascular endothelium in progressive renal disease
- PMID: 11856789
- DOI: 10.1681/ASN.V133806
Role of the microvascular endothelium in progressive renal disease
Abstract
The role of the vascular endothelium in progressive renal disease is not well understood. This review presents evidence that progressive renal disease is characterized by a progressive loss of the microvasculature. The loss of the microvasculature correlates directly with the development of glomerular and tubulointerstitial scarring. The mechanism is mediated in part by a reduction in the endothelial proliferative response, and this impairment in capillary repair is mediated by alteration in the local expression of both angiogenic (vascular endothelial growth factor) and antiangiogenic (thrombospondin 1) factors in the kidney. The alteration in balance of angiogenic growth factors is mediated by both macrophage-associated cytokines (interleukin-1beta) and vasoactive mediators. Finally, there is intriguing evidence that stimulation of angiogenesis and/or capillary repair may stabilize renal function and slow progression and that this benefit occurs independently of effects on BP or proteinuria. Therefore, angiogenic agents may represent a novel therapeutic approach for slowing the progression of renal disease.
Similar articles
-
Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.J Am Soc Nephrol. 2001 Jul;12(7):1434-1447. doi: 10.1681/ASN.V1271434. J Am Soc Nephrol. 2001. PMID: 11423572
-
Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.Am J Kidney Dis. 2001 Mar;37(3):601-11. doi: 10.1053/ajkd.2001.22087. Am J Kidney Dis. 2001. PMID: 11228186
-
Renovascular disease, microcirculation, and the progression of renal injury: role of angiogenesis.Am J Physiol Regul Integr Comp Physiol. 2011 Apr;300(4):R783-90. doi: 10.1152/ajpregu.00657.2010. Epub 2011 Feb 9. Am J Physiol Regul Integr Comp Physiol. 2011. PMID: 21307362 Free PMC article.
-
Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis.Curr Opin Nephrol Hypertens. 2003 Jan;12(1):43-9. doi: 10.1097/00041552-200301000-00008. Curr Opin Nephrol Hypertens. 2003. PMID: 12496665 Review.
-
Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?J Am Soc Hypertens. 2013 Mar-Apr;7(2):180-90. doi: 10.1016/j.jash.2013.01.004. Epub 2013 Feb 19. J Am Soc Hypertens. 2013. PMID: 23428409 Free PMC article. Review.
Cited by
-
LTBP4 affects renal fibrosis by influencing angiogenesis and altering mitochondrial structure.Cell Death Dis. 2021 Oct 13;12(10):943. doi: 10.1038/s41419-021-04214-5. Cell Death Dis. 2021. PMID: 34645813 Free PMC article.
-
The renin-angiotensin system and diabetes: an update.Vasc Health Risk Manag. 2008;4(4):787-803. Vasc Health Risk Manag. 2008. PMID: 19065996 Free PMC article. Review.
-
Urgent call for reconsideration of chronic kidney disease.World J Nephrol. 2012 Dec 6;1(6):155-9. doi: 10.5527/wjn.v1.i6.155. World J Nephrol. 2012. PMID: 24175254 Free PMC article.
-
Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression.Acta Pharmacol Sin. 2009 Jan;30(1):98-106. doi: 10.1038/aps.2008.11. Epub 2008 Dec 15. Acta Pharmacol Sin. 2009. PMID: 19079293 Free PMC article.
-
Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis.Mol Med. 2008 May-Jun;14(5-6):276-85. doi: 10.2119/2007-00111.Maluf. Mol Med. 2008. PMID: 18286166 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical